ClinicaliQ Trial Snapshot
- Pre-Clinical Validation of ChemoINTEL Unified Algorithm Chemotherapeutic Response Prediction in Patients With Colorectal Cancer — Recruiting • Oncology • NCT07830407.
- What is being tested: The ChemoINTEL assay, which measures in vitro cytotoxic drug-induced apoptosis and cell death in fresh colorectal cancer tumour cells to predict individual chemotherapeutic response in CRC patients.
- Patient eligibility overview: This prospective observational study recruits patients with colorectal cancer who require chemotherapy treatment; specific eligibility criteria focus on obtaining viable fresh tumour tissue for ex vivo drug sensitivity testing.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This is a prospective, non-randomized, observational, pre-clinical validation study. Pierian Biosciences is utilizing ChemoINTEL assay measured in vitro cytotoxic drug induced apoptosis and cell death in isolated fresh human tumour cells from patients with colorectal cancer (CRC) to predict a patient's tumour's sensitivity to specific chemotherapy drugs using the ChemoINTEL unified algorithm. Eligible patients will be assigned to one of three groups depending on the stage of disease : Group 1: Patients who have colorectal cancer and are referred for adjuvant chemotherapy after MDT discussion. Group 2: Patients with stage…
Eligibility Snapshot
- Group 1 Participants: 1. ≥18 years of age 2. Diagnosis of CRC i. Surgical resection followed by adjuvant chemotherapy ii. Biopsy followed by neoadjuvant chemo/radiotherapy and surgical resection. 3. Patients planned to receive at least 6 cycles of standard of care chemotherapy for CRC with single agent or combination of drugs listed in Table 3 following biopsy OR surgical resection 4. One solid tumor specimen is required; a total of two specimens are preferred and requested when available. Specimens will include: i. Primary solid tumor specimen (≥400 mg) ii. Adjacent normal tissue (>400mg)
- Patient signed Informed Consent Form
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.